For research use only. Not for therapeutic Use.
NF110 is a P2X3 receptor antagonist (Ki = 36 nM) and inactive toward P2Y receptors stably expressed (IC50s > 10 M). NF110 blocks alphabeta-methylene-ATP-induced currents (IC50 = 527 nM) in rat dorsal root ganglia neurons[1].
NF110 shows an activity in the human tumour cell line panel, with IC30 of 362.3 μM[2].
NF110 inhibits HMGA2-DNA interactions with an IC50 of 0.87 μM[3].
NF110 shows potency at Endogenous P2X Receptors in Rat DRG Neurons, with a peak amplitude of 675 pA[1].
| Catalog Number | M022353 |
| CAS Number | 111150-22-2 |
| Synonyms | tetrasodium;4-[[3-[[3,5-bis[(4-sulfonatophenyl)carbamoyl]phenyl]carbamoylamino]-5-[(4-sulfonatophenyl)carbamoyl]benzoyl]amino]benzenesulfonate |
| Molecular Formula | C41H28N6Na4O17S4 |
| Purity | ≥95% |
| InChI | InChI=1S/C41H32N6O17S4.4Na/c48-37(42-27-1-9-33(10-2-27)65(53,54)55)23-17-24(38(49)43-28-3-11-34(12-4-28)66(56,57)58)20-31(19-23)46-41(52)47-32-21-25(39(50)44-29-5-13-35(14-6-29)67(59,60)61)18-26(22-32)40(51)45-30-7-15-36(16-8-30)68(62,63)64;;;;/h1-22H,(H,42,48)(H,43,49)(H,44,50)(H,45,51)(H2,46,47,52)(H,53,54,55)(H,56,57,58)(H,59,60,61)(H,62,63,64);;;;/q;4*+1/p-4 |
| InChIKey | AQJHZNCSXLBXMY-UHFFFAOYSA-J |
| SMILES | C1=CC(=CC=C1NC(=O)C2=CC(=CC(=C2)NC(=O)NC3=CC(=CC(=C3)C(=O)NC4=CC=C(C=C4)S(=O)(=O)[O-])C(=O)NC5=CC=C(C=C5)S(=O)(=O)[O-])C(=O)NC6=CC=C(C=C6)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+] |
| Reference | [1]. Hausmann R, et al. The suramin analog 4,4′,4”,4”’-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups. Mol [2]. Dhar S, et al. Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients. Eur J Cancer. 2000;36(6):803-809. [3]. Su L, et al. Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays. Sci Rep. 2020;10(1):18850. Published 2020 Nov 2. |
